Abstract
Colorectal cancer is a leading cause of cancer death throughout the world. The high prevalence and mortality associated with colon cancer make effective prevention and treatment an important public health and economic concern. Among the few agents known to inhibit colorectal tumorigenesis are the nonsteroidal antiinflammatory drugs or NSAIDs, as well as newer agents such as celecoxib and rofecoxib. Both epidemiologic studies and investigations with animals show that these compounds possess marked anti-colorectal cancer properties. NSAIDS are widely known to be inhibitors of the cyclooxygenase (COX) enzymes, and it is thought that the chemopreventive effects of NSAIDs are at least in part due to this ability to inhibit COX. More recent studies, however, have suggested that NSAIDs may also exert anti-cancer effects through mechanisms independent of COX inhibition. COX-dependent and COX-independent mechanisms are not mutually exclusive and it is likely that both are involved in the biological activity of NSAIDs.
Keywords: cyclooxygenase, colon, cancer, chemoprevention, apoptosis, arachidonic acid, nonsteroidal anti-inflammatory drug
Current Cancer Drug Targets
Title: Cyclooxygenase Inhibition and Mechanisms of Colorectal Cancer Prevention
Volume: 3 Issue: 6
Author(s): Timothy A. Chan
Affiliation:
Keywords: cyclooxygenase, colon, cancer, chemoprevention, apoptosis, arachidonic acid, nonsteroidal anti-inflammatory drug
Abstract: Colorectal cancer is a leading cause of cancer death throughout the world. The high prevalence and mortality associated with colon cancer make effective prevention and treatment an important public health and economic concern. Among the few agents known to inhibit colorectal tumorigenesis are the nonsteroidal antiinflammatory drugs or NSAIDs, as well as newer agents such as celecoxib and rofecoxib. Both epidemiologic studies and investigations with animals show that these compounds possess marked anti-colorectal cancer properties. NSAIDS are widely known to be inhibitors of the cyclooxygenase (COX) enzymes, and it is thought that the chemopreventive effects of NSAIDs are at least in part due to this ability to inhibit COX. More recent studies, however, have suggested that NSAIDs may also exert anti-cancer effects through mechanisms independent of COX inhibition. COX-dependent and COX-independent mechanisms are not mutually exclusive and it is likely that both are involved in the biological activity of NSAIDs.
Export Options
About this article
Cite this article as:
Chan A. Timothy, Cyclooxygenase Inhibition and Mechanisms of Colorectal Cancer Prevention, Current Cancer Drug Targets 2003; 3 (6) . https://dx.doi.org/10.2174/1568009033481723
DOI https://dx.doi.org/10.2174/1568009033481723 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
A Review on the Techniques for Characterizing and Predicting Human Genomic DNA Methylation
Current Bioinformatics Recent Advances in Drug Design of Epidermal Growth Factor Receptor Inhibitors
Current Medicinal Chemistry Stromal Cell-Derived Factor (SDF) 2 and the Endoplasmic Reticulum Stress Response of Trophoblast Cells in Gestational Diabetes Mellitus and <i>In vitro</i> Hyperglycaemic Condition
Current Vascular Pharmacology Meet Our Editorial Board Member
Protein & Peptide Letters Colorectal Cancer: Causes and Evidence of Chemopreventive Treatments
Current Pharmaceutical Biotechnology A Mechanistic Overview on Male Infertility and Germ Cell Cancers
Current Pharmaceutical Design Studies of NVP-BEZ235 in Melanoma
Current Cancer Drug Targets Role of Stem Cells in Colorectal Cancer Progression and Prognostic and Predictive Characteristics of Stem Cell Markers in Colorectal Cancer
Current Stem Cell Research & Therapy Metabolism of Acrylamide: Interindividual and Interspecies Differences as Well as the Application as Biomarkers
Current Drug Metabolism Development of Molecular Targeted Anticancer Agents: Successes, Failures and Future Directions
Current Pharmaceutical Design Combined Treatment with PPAR-γ Agonists in Pancreatic Cancer: A Glimmer of Hope for Cancer Therapy?
Current Cancer Drug Targets Emerging Role and Targeting of Carcinoembryonic Antigen-related Cell Adhesion Molecule 6 (CEACAM6) in Human Malignancies
Clinical Cancer Drugs Technologies for Translational Imaging Using Generators in Oncology
Recent Patents on Anti-Cancer Drug Discovery Collateral Damage Control in Cancer Therapy: Defining the Stem Identity in Gliomas
Current Pharmaceutical Design PEGylated Liposomes of Meloxicam: Optimization by Quality by Design, in vitro Characterization and Cytotoxicity Evaluation
Pharmaceutical Nanotechnology TRAIL-Based Therapeutic Approaches for the Treatment of Pediatric Malignancies
Current Medicinal Chemistry Imatinib Mesylate for the Treatment of Solid Tumours: Recent Trials and Future Directions
Current Enzyme Inhibition Recent Advances in the Research and Development of B-Raf Inhibitors
Current Medicinal Chemistry Adhesion Molecules in Lung Cancer: Implications in the Pathogenesis and Management
Current Pharmaceutical Design Clinico-Pathologic and Biologic Predictors of EGFR Inhibitors Activity and Efficacy in Lung and in Colorectal Cancer
Current Signal Transduction Therapy